EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab By Ogkologos - May 8, 2026 85 0 Facebook Twitter Google+ Pinterest WhatsApp It is a cancer medicine used to treat adult patients with multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR What to Know About Cancer Care and Research for People 65+:... February 28, 2023 “Hero” Nurses Plan Wedding In 24 Hours So Dying Patient Can... May 10, 2019 FDA Approves Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma March 12, 2021 French Senate Committee Backs ESMO Call to Revise EU Regulation to... June 17, 2025 Load more HOT NEWS Scientists Discover How Air Pollution May Trigger Lung Cancer in Never-Smokers... HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours Poorer Survival in Obese Colorectal Cancer Patients Possibly Linked to Lower... What is Mindfulness?
